Institute of Surgical Sciences, University of Bergen, Bergen, Norway.
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e161-6. doi: 10.1016/j.ijrobp.2012.03.047. Epub 2012 Jun 8.
Gamma Knife radiosurgery (GKRS) has been increasingly used in the treatment of vestibular schwannoma (VS). Very few studies relate tumor control and post-treatment growth rates to pretreatment growth rates.
We prospectively included 45 consecutive VS patients who were initially treated conservatively and then received GKRS between 2000 and 2007 because of demonstrated tumor growth. Pretreatment and post-treatment tumor volumes were estimated. Patients underwent audiograms, reported their symptoms, and responded to the Short Form General Health Survey (SF-36) questionnaire on each visit.
Volume doubling times before and after treatment were 1.36 years (95% confidence intervals, 1.14-1.68) and -13.1 years (95% confidence intervals, -111.0 to -6.94), respectively. Tumor control, defined as a post-GKRS growth rate ≤ 0, was achieved in 71.1% of patients, with highest odds for tumor control among older patients and those with larger tumors. The 5-year retreatment-free survival rate was 93.9% (95% confidence intervals, 76.5-98.5). None of the clinical endpoints investigated showed statistically significant changes after GKRS, but improvement was seen in a few SF-36 parameters.
GKRS alters the natural course of the tumor by reducing growth. Mathematic models yield poorer tumor control rates than those found by clinical assessment. Symptoms were unaffected by treatment, but quality of life was improved.
伽玛刀放射外科(GKRS)已越来越多地用于治疗前庭神经鞘瘤(VS)。很少有研究将肿瘤控制和治疗后生长率与治疗前生长率联系起来。
我们前瞻性地纳入了 45 例连续的 VS 患者,这些患者最初接受保守治疗,然后在 2000 年至 2007 年间因肿瘤生长而接受 GKRS 治疗。评估了治疗前后的肿瘤体积。患者进行了听力图检查,报告了他们的症状,并在每次就诊时回答了简短形式的一般健康调查问卷(SF-36)。
治疗前后的体积倍增时间分别为 1.36 年(95%置信区间,1.14-1.68)和-13.1 年(95%置信区间,-111.0 至-6.94)。肿瘤控制定义为 GKRS 后生长率≤0,71.1%的患者达到肿瘤控制,年龄较大和肿瘤较大的患者肿瘤控制的几率更高。5 年无再治疗生存率为 93.9%(95%置信区间,76.5-98.5)。调查的临床终点均未显示 GKRS 后有统计学意义的变化,但 SF-36 的一些参数有所改善。
GKRS 通过减少肿瘤生长来改变肿瘤的自然病程。数学模型得出的肿瘤控制率低于临床评估的结果。治疗对症状没有影响,但生活质量得到了改善。